AI Insight
Researchers at the UW-Madison Department of Chemistry's Gellman Group are investigating how drug molecules behave once they reach their cellular targets, specifically focusing on how drugs interact with receptor proteins on cell surfaces. The research examines drug peptides that can activate receptors without adopting the complete helical (spiral) structure previously thought to be necessary for receptor activation. This challenges conventional understanding of the structural requirements for drug-receptor interactions that enable cellular communication and information transfer.
Why it matters
Understanding that drug peptides can function effectively without full helical structures could enable the design of new therapeutic compounds with greater flexibility in their molecular architecture. This knowledge may lead to more efficient drug development by expanding the range of viable molecular structures that can successfully modulate receptor proteins involved in disease processes.
Understand the Science
When many of us think about how drugs work in the body, we may first think about how a drug gets into the body, such as a pill versus an injection. In the Gellman Group at the UW–Madison Department of Chemistry, researchers are instead thinking about how a drug behaves after it reaches its target, which is critical for effective drug performance. The cells in our bodies must receive and respond to information from their environment for healthy function, and when information flow is disrupted, illness can result. Most of the information is contained in molecules that engage with receptor proteins on cell surfaces. Many medicines work by modifying information transfer at specific receptor proteins.
Source: Drug peptides defy shape rules, activating receptors without full spiral form